We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Tilray Brands, Inc.
Consumer Staples · Pharmaceuticals
Structural: Largest Canadian LP by revenue, #1 cannabis market share in Canada and Germany medical, top-5 US craft brewer post the 2023 ABInBev brand acquisition ($85M cash for 8 craft beer brands). Beverage-alcohol segment (~$200M annualized) provides non-cannabis cashflow + US distribution rails ready for federal cannabis legalization.
International medical cannabis exposure via Aphria Germany + Tilray Portugal + CC Pharma EU distribution.
Bull case:
- US federal rescheduling (Schedule III) or SAFE Banking removes 280E tax penalty and unlocks institutional capital
- German adult-use rollout (legalized April 2024) drives EU medical-to-rec optionality where Tilray holds #1 medical share
- Beverage portfolio + distribution rails = ready-made US cannabis-infused beverage platform once legal
- $250M+ cash + convertible notes restructured; survival risk lower than smaller LPs
- M&A optionality: HEXO + Truss + ABI craft brand consolidation playbook
Bear case:
- Canadian rec market remains oversupplied with price compression; segment gross margin pressured
- Beverage segment growth flat ex-acquisitions; craft beer category in secular decline
- Chronic share dilution (~946M shares vs ~100M at 2018 IPO) funds losses, not growth
- US legalization timeline keeps slipping; rescheduling stuck in DEA review
- Persistent adjusted EBITDA losses on a GAAP basis; cash burn requires continued capital raises
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for TLRY - only listicles and opinion pieces, which we filter out by default. See everything anyway.